|
|
Exosomal Drug Delivery
|
5R44CA221487-02
|
$1,000,000
|
$1,000,000
|
SPENCER, WENDY
|
3P BIOTECHNOLOGIES, INC.
|
|
|
Targeted Therapy for Non Small Cell Lung Carcinoma: Human Phase 1 safety and dose escalation studies
|
5R44CA162629-03
|
$833,374
|
$833,374
|
SERRERO, GINETTE
|
A AND G PHARMACEUTICAL, INC.
|
|
|
AVGN7, a Novel Gene Therapeutic for Treating Cancer Cachexia
|
5R44CA221539-02
|
$660,235
|
$217,878
|
RODGERS, BUEL
|
AAVOGEN, INC.
|
|
|
Personalized precision dosing of biologic therapies in oncology
|
5R44CA217336-02
|
$720,363
|
$720,363
|
MESSMER, BRADLEY
|
ABREOS BIOSCIENCES, INC.
|
|
|
Precisely Shaped Acoustic Ablation of Tumors Under 3D Ultrasound Image Guidance
|
3R44CA134169-04S1
|
$82,590
|
|
Burdette, Everette
|
ACOUSTIC MEDSYSTEMS, INC.
|
|
|
Antibody targeting of ADAM8 for treatment of triple-negative breast cancer
|
2R44CA200161-02A1
|
$1,000,000
|
$1,000,000
|
SONENSHEIN, GAIL
|
ADECTO PHARMACEUTICALS, INC.
|
|
|
Antibody targeting of ADAM8 for treatment of triple-negative breast cancer
|
3R41CA200161-01A1S3
|
$3,000
|
$3,000
|
SONENSHEIN, GAIL
|
ADECTO PHARMACEUTICALS, INC.
|
|
|
Implantable iontophoresis chemotherapy delivery device for direct infusion of gemcitabine into pancreatic adenocarcinoma: Device development and First-in-Human clinical trial
|
4R44CA224460-02
|
$1,111,364
|
$1,111,364
|
DAUNCH, WILLIAM
|
ADVANCED CHEMOTHERAPY TECHNOLOGIES, INC.
|
|
|
Immuno-Oncology for Pancreatic Cancer: A Combination Clinical Trial with Chemotherapy and Radiation
|
4R44CA203336-02
|
$659,516
|
$659,516
|
AGUILAR-CORDOVA, ESTUARDO
|
ADVANTAGENE, INC
|
|
|
A Novel Immunotherapy Targeting Cancer Stem Cells for the Treatment of Triple-Negative Breast Cancer
|
1R44CA224835-01A1
|
$298,864
|
$298,864
|
PERICLE, FEDERICA
|
AGILVAX, INC.
|
|
|
MOTILITY AND INVASION
|
3P01CA100324-09S1
|
$72,007
|
|
CONDEELIS, JOHN
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
|
Core Support for Cancer Center
|
3P30CA013330-39S1
|
$249,624
|
|
GOLDMAN, Israel
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
|
Core Support for Cancer Center
|
3P30CA013330-39S2
|
$249,624
|
|
GOLDMAN, Israel
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
|
Core Support for Cancer Center
|
3P30CA013330-39S3
|
$74,922
|
|
GOLDMAN, Israel
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
|
Core Support for Cancer Center
|
5P30CA013330-39
|
$3,725,702
|
|
GOLDMAN, Israel
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
|
MR Spectroscopy to Evaluate Liver Repopulation by Transplanted Hepatocytes
|
5R33CA121051-04
|
$466,808
|
|
GUHA, CHANDAN
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
|
A Pilot Study of Positively Smoke Free on the Web (PSFW) for HIV-infected Smokers
|
1R21CA163100-01
|
|
|
Shuter, Jonathan
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
|
EASTERN COOPERATIVE ONCOLOGY GROUP
|
5U10CA014958-37
|
$99,689
|
|
Sparano, Joseph
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
|
Core Support for Cancer Center
|
3P30CA013330-45S1
|
$3,646,138
|
$109,384
|
GOLDMAN, ISRAEL
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
Inhibition of Senescence to Increase Cancer Cell Death: A New Paradigm
|
5R01CA077263-19
|
$417,500
|
$417,500
|
MCDAID, HAYLEY
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
Expression-Based Multi-Gene Signatures for CRC Recurrence and Chemoselection
|
5R44CA119565-06
|
$999,610
|
|
Sears, Christopher
|
AMBERGEN, INC
|
|
|
Community Clinical Oncology Program
|
5U10CA037422-24
|
$4,282,002
|
|
BRUNER, DEBORAH
|
AMERICAN COLLEGE OF RADIOLOGY
|
|
|
Radiation Therapy Oncology Group
|
3U10CA021661-35S1
|
$2,923,989
|
|
Curran, Walter
|
AMERICAN COLLEGE OF RADIOLOGY
|
|
|
Radiation Therapy Oncology Group
|
5U10CA021661-35
|
$10,630,221
|
|
Curran, Walter
|
AMERICAN COLLEGE OF RADIOLOGY
|
|
|
American College of Radiology Imaging Network
|
5U01CA080098-13
|
$7,455,878
|
|
Schnall, Mitchell
|
AMERICAN COLLEGE OF RADIOLOGY
|
|
|
Geospatial Frontiers in Health and Social Environments
|
1R13CA162823-01
|
|
|
Richardson, Douglas
|
ASSOCIATION OF AMERICAN GEOGRAPHERS
|
|
|
Identification of microRNA Biomarkers for Colon Cancer Recurrence Risk Stratifica
|
4R44CA138038-03
|
$590,860
|
|
Mambo, Elizabeth
|
ASURAGEN, INC.
|
|
|
IDO-Expressing Immunoregulatory Dendritic Cells
|
5R01CA103320-15
|
$307,800
|
$307,800
|
MUNN, DAVID
|
AUGUSTA UNIVERSITY
|
|
|
Chemotherapy-induced MDSCs and antitumor immunity
|
5R01CA215523-02
|
$347,700
|
$347,700
|
ZHOU, GANG
|
AUGUSTA UNIVERSITY
|
|
|
Bay Area Tumor Institute CCOP
|
5U10CA045461-22
|
$406,165
|
|
Feusner, James
|
BAY AREA TUMOR INSTITUTE
|
|
|
Integrative Molecular Epidemiology of Neurocognitive Outcomes in Acute Lymphoblastic Leukemia
|
1K07CA218362-01A1
|
$166,043
|
$166,043
|
BROWN, AUSTIN
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
PDX-1 is a Therapeutic Target for Pancreatic Cancer
|
5R01CA095731-09
|
$266,570
|
|
BRUNICARDI, FRANCIS
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Crosstalk between the ER Stress Response and Mitochondrial Fatty Acid Oxidation in MYC-driven Breast Cancer
|
1R37CA228304-01
|
$362,569
|
$181,285
|
CHEN, XI
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Guideline-based surveillance and treatment of hepatocellular carcinoma
|
1R01CA160738-01
|
$292,264
|
|
Davila, Jessica
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
(PQ5) Exploring the Biological Distinctions between HIV-related and Endemic Pediatric Kaposi Sarcoma in a Kaposi Sarcoma-Associated Herpesvirus-Endemic Region of Africa
|
5R21CA217137-02
|
$196,947
|
$196,947
|
EL-MALLAWANY, NADER
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
MICROSCALED PROTEOGENOMICS FOR CANCER CLINICAL TRIALS
|
5U01CA214125-02
|
$1,413,657
|
$1,413,657
|
ELLIS, MATTHEW
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Preclinical Analyses of NAD Kinase as a Redox Vulnerability for the Treatment of Pancreatic Cancer
|
5R01CA211176-02
|
$362,569
|
$362,569
|
ELSEA, SARAH
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
SPORE in Lymphoma
|
5P50CA126752-12
|
$2,297,796
|
$275,736
|
HESLOP, HELEN
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Neurocognitive Outcomes Following Proton Beam Radiation Therapy for Treatment of
|
1K07CA157923-01
|
$148,426
|
|
KAHALLEY, LISA
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-05S1
|
$75,000
|
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-12S1
|
$118,875
|
$15,454
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-12S2
|
$249,997
|
$32,500
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-12S3
|
$125,004
|
$16,251
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Baylor College of Medicine Cancer Center
|
5P30CA125123-05
|
$2,934,758
|
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Baylor College of Medicine Cancer Center
|
5P30CA125123-12
|
$3,203,119
|
$416,405
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Translational Research in Breast Cancer (SPORE)
|
5P50CA186784-05
|
$2,251,410
|
$270,169
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Pediatric Clinical Oncology Research Training Program
|
3K12CA090433-10S1
|
$134,042
|
|
Poplack, David
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Pediatric Clinical Oncology Research Training Program
|
5K12CA090433-10
|
$475,607
|
|
Poplack, David
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Using Stat3 Signaling Profiles to Understand Chemotherapy Resistance in AML
|
5R01CA175026-05
|
$379,294
|
$379,294
|
REDELL, MICHELE
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Adult Neurobehavioral Late Effects of Pediatric Low Grade Brain Tumors
|
5R01CA132899-03
|
$340,627
|
|
Ris, M
|
BAYLOR COLLEGE OF MEDICINE
|
|
Total relevant funding to Chemotherapy for this search: $339,941,866
|
